Advertisement

Importance of asking questions about erectile dysfunction

      Recent estimates from the National Institutes of Health suggest that about 30 million men in the United States have partial or complete erectile dysfunction (ED).
      NIH Consensus Development Panel on Impotence
      Impotence.
      Moreover, data from the Massachusetts Male Aging Study indicated that up to 52% of the male study population aged 40 to 70 years had some degree of ED.
      • Feldman H.A.
      • Goldstein I.
      • Hatzichristou D.G.
      • Krane R.J.
      • McKinlay J.B.
      Impotence and its medical and psychosocial correlates results of the Massachusetts Male Aging Study.
      However, Laumann et al,
      • Laumann E.O.
      • Paik A.
      • Rosen R.C.
      Sexual dysfunction in the United States prevalence and predictors.
      analyzing data from the National Health and Social Life Survey, found that only about 1 in 10 men with ED between 18 and 59 years of age actually went to a physician for consultation about their sexual dysfunction. Considering the large number of affected men and the growing awareness through the media of options available for treatment, why are surprisingly few men seeking help for this problem? One answer may lie in the results of a US survey of 500 adults, aged ≥25 years, which showed that as many as 71% “thought their doctor would dismiss any concerns about sexual problems they might bring up.”
      • Marwick C.
      Survey says patients expect little physician help on sex.
      In addition, several other reasons have been suggested for not seeking help:
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • NIH Consensus Development Panel on Impotence
        Impotence.
        JAMA. 1993; 270: 83-90
        • Feldman H.A.
        • Goldstein I.
        • Hatzichristou D.G.
        • Krane R.J.
        • McKinlay J.B.
        Impotence and its medical and psychosocial correlates.
        J Urol. 1994; 151: 54-61
        • Laumann E.O.
        • Paik A.
        • Rosen R.C.
        Sexual dysfunction in the United States.
        JAMA. 1999; 281: 537-544
        • Marwick C.
        Survey says patients expect little physician help on sex.
        JAMA. 1999; 281: 2173-2174
      1. Baldwin KC, Ginsberg PC, Harkaway RC. Underreporting of erectile dysfunction among men with unrelated urologic conditions. Abstract presented at Annual Meeting of the American Urological Association; April 29-May 4, 2000, Atlanta, GA.

        • Dewire D.M.
        Evaluation and treatment of erectile dysfunction.
        Am Fam Physician. 1996; 53: 2101-2106
      2. Pritzker MR. The penile stress test: a window to the hearts of man? 72nd Scientific Sessions of the American Heart Association; November 7–10, 1999; Atlanta, GA. Abstract 104561.

      3. Billups K, Friedrich S. Assessment of fasting lipid panels and Doppler ultrasound testing in men presenting with erectile dysfunction and no other medical problems. Abstract presented at Annual Meeting of the American Urological Association; April 29-May 4, 2000, Atlanta, GA.

        • Rosen R.C.
        • Cappelleri J.C.
        • Smith M.D.
        • Lipsky J.
        • Peña B.N.
        Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction.
        Int J Impot Res. 1999; 11: 319-326
        • Process of Care Consensus Panel
        Position paper.
        Int J Impot Res. 1999; 11: 59-74
        • Jackson G.
        Erectile dysfunction and cardiovascular disease.
        Int J Clin Pract. 1999; 53: 363-368
        • Jackson G.
        • Betteridge J.
        • Dean J.
        • Hall R.
        • Holdright D.
        • Holmes S.
        • Kirby M.
        • Riley A.
        • Sever P.
        A systematic approach to erectile dysfunction in the cardiovascular patient.
        Int J Clin Pract. 1999; 53: 445-451
        • Goldstein I.
        • Lue T.F.
        • Padma-Nathan H.
        • Rosen R.C.
        • Steers W.D.
        • Wicker P.A.
        • Sildenafil Study Group
        Oral sildenafil in the treatment of erectile dysfunction.
        N Engl J Med. 1998; 338: 1397-1404
        • Zusman R.M.
        • Morales A.
        • Glasser D.B.
        • Osterloh I.H.
        Overall cardiovascular profile of sildenafil citrate.
        Am J Cardiol. 1999; 83: 35C-44C
      4. Kloner RA, Brown M, Prisant LM, Collins M, for the Sildenafil Study Group. Efficacy and safety of Viagra® (sildenafil citrate) in patients with erectile dysfunction taking concomitant antihypertensive therapy. Hypertension; in press.

        • Mittleman M.A.
        • Glasser D.B.
        • Orazem J.
        • Collins M.
        Incidence of myocardial infarction and death in 53 clinical trials of Viagra® (sildenafil citrate) (abstr).
        J Am Coll Cardiol. 2000; 35: 302
        • Conti R.C.
        • Pepine C.J.
        • Sweeney M.
        Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with coronary heart disease.
        Am J Cardiol. 1999; 83: 29C-34C
        • Olsson A.M.
        • Persson C.-A.
        Efficacy and safety of Viagra® (sildenafil citrate) in men with cardiovascular disease and erectile dysfunction (abstr).
        J Am Coll Cardiol. 2000; 35: 329
      5. Herrmann HC, Catella-Lawson F, Chang G, Kapoor S, Klugherz BD, Kolansky DM, Kumar AG, Mahoney PD. Systemic, pulmonary, and coronary hemodynamics and platelet effects of oral sildenafil citrate (Viagra) in men with severe coronary artery disease. 72nd Scientific Sessions of the American Heart Association; November 7–10, 1999; Atlanta, Georgia. Abstract #2177.

      6. Lepore JJ, Pereira N, Maroo A, Ginns I, Bigatello IM, Dec GW, Rubin R, Zapol WM, Bloch KD, Semigran MJ. Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilation by inhaled nitric oxide in patients with pulmonary hypertension. 72nd Scientific Sessions of the American Heart Association; November 7–10, 1999; Atlanta, Georgia. Abstract #107514.

        • Pelliccia F.
        • Leonardo F.
        • Pagnotta P.
        • Patrizi R.
        • Cerquetani E.
        • Chierchia S.L.
        • Rosano G.M.C.
        Effects of phosphodiesterase-5 inhibition on myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers.
        J Am Coll Cardiol. 2000; 35 (abstr): 339
        • Cheitlin M.D.
        • Hutter A.M.
        • Brindis R.G.
        • Ganz P.
        • Kaul S.
        • Russell Jr, R.O.
        • Zusman R.M.
        ACC/AHA Expert Consensus Document.
        J Am Coll Cardiol. 1999; 33: 273-282
        • Kloner R.A.
        • Zusman R.M.
        Cardiovascular effects of sildenafil citrate and recommendations for its use.
        Am J Cardiol. 1999; 84: 11N-17N
        • Mittleman M.A.
        • Siscovick D.S.
        Physical exertion as a trigger of myocardial infarction and sudden cardiac death.
        Cardiol Clin. 1996; 14: 263-270
        • Drory Y.
        • Shapira I.
        • Fisman E.
        • Pines A.
        Myocardial ischemia during sexual activity in patients with coronary artery disease.
        Am J Cardiol. 1995; 75: 835-837